発表論文
PUBLICATIONS

発表論文 Publications ▸ 研究紹介 Researches ▸ プロトコール Protocol ▸ コラム Column ▸


2022

  1. Iida K, Tsuchiya A, Tamura M, Yamamoto K, Kawata S, Ishihara-Sugano M, Kato M, Kitamura T, Goyama S.
    RUNX1 Inhibition Using Lipid Nanoparticle-Mediated Silencing RNA Delivery as an Effective Treatment for Acute Leukemias. Experimental Hematology (in press)
  2. Hayashi Y, Kawabata KC, Tanaka Y, Uehara Y, Mabuchi Y, Murakami K, Nishiyama A, Kiryu S, Yoshioka Y, Ota Y, Sugiyama T, Mikami K, Tamura M, Fukushima T, Asada S, Takeda R, Kunisaki Y, Fukuyama T, Yokoyama K, Uchida T, Hagihara M, Ohno N, Usuki K, Tojo A, Katayama Y, Goyama S, Arai F, Tamura T, Nagasawa T, Ochiya T, Inoue D, Kitamura T.
    MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis. Cell Reports. 39(6):110805 (2022).
  3. Liu X, Sato N, Shimosato Y, Wang TW, Denda T, Chang YH, Yabushita T, Fujino T, Asada S, Tanaka Y, Fukuyama T, Enomoto Y, Ota Y, Sakamoto T, Kitamura T, Goyama S.
    CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Science 113(4):1182-1194 (2022).
  4. Shull LC, Lencer ES, Kim HM, Goyama S, Kurokawa M, Costello JC, Jones K, Artinger KB.
    PRDM paralogs antagonistically balance Wnt/β-catenin activity during craniofacial chondrocyte differentiation. Development 149(4): dev200082 (2022).
  5. Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Takaku T, Kitamura T.
    Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nature Communication. 12;13(1):271 (2022)
  6. 合山進　造血器腫瘍における免疫チェックポイント分子の検出と治療への応用　血液内科　84(5)　702-708 (2022)

2021

  1. Fukushima T, Tanaka Y, Adachi K, Masuyama N, Tsuchiya A, Asada S, Ishiguro S, Mori H, Seki M, Yachie N, Goyama S, Kitamura T.
    CRISPR/Cas9-mediated base-editing enables a chain reaction through sequential repair of sgRNA scaffold mutations. Scientific Reports. 11(1):23889 (2021).
  2. Yamamoto K, Goyama S, Asada S, Fujino T, Yonezawa T, Sato N, Takeda R, Tsuchiya A, Fukuyama T, Tanaka Y, Yokoyama A, Toya H, Kon A, Nannya Y, Onoguchi-Mizutani R, Nakagawa S, Hirose T, Ogawa S, Akimitsu N, Kitamura T.
    A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Reports 36(8):109576 (2021).
  3. Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, Matsumoto A, Yamaguchi K, Isobe Y, Tsuchiya A, Shikata S, Sato N, Morinaga H, Fukuyama T, Tanaka Y, Fukushima T, Takeda R, Yamamoto K, Honda H, Nishimura EK, Furukawa Y, Shibata T, Abdel-Wahab O, Suematsu M, Kitamura T.
    Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature Communications 12(1):1826, 2021.
  4. Backx E, Wauters E, Baldan J, Van Bulck M, Michiels E, Heremans Y, De Paep DL, Kurokawa M, Goyama S, Bouwens L, Jacquemin P, Houbracken I, Rooman I.
    MECOM permits pancreatic acinar cell dedifferentiation avoiding cell death under stress conditions. Cell Death & Differentiation 28(9):2601-2615 (2021).
  5. 合山進　がん幹細胞と腫瘍免疫 Journal of Japanese Biochemical Society 93(1): 162-166 (2021).
  6. 合山進　急性骨髄性白血病に対する分子標的治療　医学のあゆみ278(13), 1097 -1101 (2021).
  7. 合山進　急性骨髄性白血病：CBF白血病における治療標的　血液内科83(3), 383-389, 2021.

2020

  1. Tanaka Y, Mikami K, Adachi K, Fukushima T, Fukuyama T, Goyama S, Kitamura T.
    Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model andchronic myeloid leukemia stem cells. Experimental Hematology 90:46-51, 2020.
  2. Takeda R, Asada S, Park SJ, Yokoyama A, Becker HJ, Kanai A, Visconte V, HershbergerCE, Hayashi Y, Yonezawa T, Tamura M, Fukushima T, Tanaka Y, Fukuyama T, MatsumotoA, Yamasaki S, Nakai K, Yamazaki S, Inaba T, Shibata T, Inoue D, Honda H, Goyama S, Maciejewski JP, Kitamura T.
    HHEX Promotes Myeloid Transformation in Cooperation withMutant ASXL1. Blood 136 (14):1670-1684, 2020.
  3. Kawashima M, Carreras J, Higuchi H, Kotaki R, Hoshina T, Okuyama K, Suzuki N, Kakizaki M, Miyatake Y, Ando K, Nakayama M, Umezu S, Horie R, Higuchi Y, Katagiri K, Goyama S, Kitamura T, Chamoto K, Yano S, Nakamura N, Kotani A.
    PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 34(9):2405-2417 (2020).
  4. Ye J, Huang A, Wang H, Zhang AMY, Huang X, Lan Q, Sato T, Goyama S, Kurokawa M, Deng C, Sander M, Schaeffer DF, Li W, Kopp JL, Xie R.
    PRDM3 Attenuates Pancreatitis and Pancreatic Tumorigenesis by Regulating Inflammatory Response. Cell Death & Disease 11(3):187 (2020).
  5. Shull LC, Sen R, Menzel J, Goyama S, Kurokawa M, Artinger KB.
    The conserved and divergent roles of Prdm3 and Prdm16 in zebrafish and mouse craniofacial development. Developmental Biology 461(2):132-144, 2020.
  6. Goyama S.
    Acute myeloid leukemia stem cells from genomic and immunological perspectives. Rinsho Ketsueki 61(9): 1130-1137, 2020
  7. Goyama S.
    Acute myeloid leukemia stem cells. Rinsho Ketsueki 61(4): 336-342, 2020.
  8. 合山進　MDSおよびMPNにおけるdel(20q)によるHippoキナーゼ発現低下と骨髄線維化を促進する慢性炎症　血液内科81(1), 79-84, 2020.
  9. 田村萌、浅田修平、北村俊雄、合山進　骨髄系腫瘍におけるp53変異とデシタビン感受性　血液内科81(4), 541-547, 2020
  10. 合山進　白血病幹細胞　日本臨床78巻増刊号3, 134-139, 2020
  11. 合山進 がん幹細胞のエピゲノム制御 医学のあゆみ 273(5) 368-374 (2020).

2019

  1. Fukushima T, *Tanaka Y, Hamey FK, Chang CH, Oki T, Asada S, Hayashi Y, Fujino T, Yonezawa T, Takeda R, Kawabata KC, Fukuyama T, Umemoto T, Takubo K, Takizawa H, Goyama S, Ishihama Y, Honda H, Göttgens B, Kitamura T.
    Discrimination of dormant and active hematopoietic stem cells by G0 markers reveals dormancy regulation by cytoplasmic calcium. Cell Reports 29(12) 4144-4158.e7 (2019).
  2. Hayashi Y, *Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, Fukuyama T, Wunderlich M, O’Brien E, Mizukawa B, Yamazaki S, Matsumoto A, Yamasaki S, Shibata T, Matsuda K, Sashida G, Takizawa H, *Kitamura T.
    Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nature Communications 10(1): 4869 (2019).
  3. Tamura M, Yonezawa T, Liu X, Asada S, Hayashi Y, Fukuyama T, Tanaka Y, Kitamura T, *Goyama S.
    Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms. Scientific Reports 9(1): 8171 (2019)
  4. *Goyama S, Schibler J, Mulloy JC.
    Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity. Experimental Hematology 72: 27-35 (2019).
  5. Asada S, Fujino T, Goyama S, Kitamura T.
    The role of ASXL1 in hematopoiesis and myeloid malignancies. Cellular and Molecular Life Sciences 76(13): 2511-2523 (2019)

2018

  1. Saika M, Inoue D, Nagase R, Sato N, Tsuchiya A, Yabushita T, *Kitamura T, *Goyama S.
    ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation. Scientific Reports 8(1): 15873 (2018).
  2. Yonezawa T, Takahashi H, Shikata S, Sawasaki T, Kitamura T, *Goyama S.
    The ubiquitin ligase RNF38 promotes RUNX1 ubiquitination and enhances RUNX1-mediated suppression of erythroid transcription programs. Biochemical and Biophysical Research Communications 505(3): 905-909 (2018).
  3. Asada S, Goyama S, Inoue D, Shikata S, Takeda R, Fukushima T, Yonezawa T, Fujino T, Hayashi Y, Kawabata KC, Fukuyama T, Tanaka Y, Yokoyama A, Yamazaki S, Kozuka-Hata H, Oyama M, Kojima S, Kawazu M, Mano H, *Kitamura T.
    Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nature Communications 9(1): 2733 (2018).
  4. Osumi T, Tsujimoto SI, Tamura M, Uchiyama M, Nakabayashi K, Okamura K, Yoshida M, Tomizawa D, Watanabe A, Takahashi H, Hori T, Yamamoto S, Hamamoto K, Migita M, Ogata-Kawata H, Uchiyama T, Kizawa H, Ueno-Yokohata H, Shirai R, Seki M, Oki K, Takita J, Inukai T, Ogawa S, Kitamura T, Matsumoto K, Hata K, Kiyokawa N, Goyama S, *Kato M.
    Recurrent RARB Translocations in Acute Promyelocytic Leukemia lacking RARA Translocation. Cancer Research 78(16): 4452-4458 (2018).
  5. Nagase R, Inoue D, Pastore A, Fujino T, Hou HA, Yamasaki N, Goyama S, Saika M, Kanai A, Sera Y, Horikawa S, Ota Y, Asada S, Hayashi Y, Kawabata KC, Takeda R, Tien HF, Honda H, Abdel-Wahab O, *Kitamura T.
    Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Journal of Experimental Medicine 215(6): 1729-1747 (2018).
  6. *Inoue D, Fujino T, Sheridan P, Zhang YZ, Nagase R, Horikawa S, Li Z, Matsui H, Kanai A, Saika M, Yamaguchi R, Kozuka-Hata H, Kawabata KC, Yokoyama A, Goyama S, Inaba T, Imoto S, Miyano S, Xu M, Yang FC, Oyama M, *Kitamura T.
    A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies. Leukemia 32(6): 1327-1337 (2018).
  7. Osumi T, Tsujimoto SI, Nakabayashi K, Taniguchi M, Shirai R, Yoshida M, Uchiyama T, Nagasawa J, Goyama S, Yoshioka T, Tomizawa D, Kurokawa M, Matsubara Y, Kiyokawa N, Matsumoto K, Hata K, *Kato M.
    Somatic MECOM mosaicism in a patient with congenital bone marrow failure without a radial abnormality. Pediatric Blood and Cancer 65(6): e26959 (2018).
  8. Miyashita K, Kitajima K, Goyama S, Kitamura T, *Hara T.
    Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. Biochemical and Biophysical Research Communications 495(3): 2310-2316 (2018).
  9. Kawabata KC, Hayashi Y, Inoue D, Meguro H, Sakurai H, Fukuyama T, Tanaka Y, Asada S, Fukushima T, Nagase R, Takeda R, Harada Y, Kitaura J, Goyama S, Harada H, Aburatani H, *Kitamura T.
    High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis. Leukemia 32(2): 419-428 (2018).

2017

  1. Yonezawa T, Takahashi H, Shikata S, Liu X, Tamura M, Asada S, Fukushima T, Fukuyama T, Tanaka Y, Sawasaki T, Kitamura T, *Goyama S.
    The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1. Journal of Biological Chemistry 292(30): 12528-12541 (2017).
  2. Goyama S, Shrestha M, Schibler J, Rosenfeldt L, Miller W, O’Brien E, Mizukawa B, Kitamura T, *Palumbo JS, *Mulloy JC.
    Protease-activated receptor 1 (PAR-1) inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. Oncogene 36(18): 2589-2598 (2017).
  3. Shan L, Mulloy JC, *Goyama S.
    RUNX1-ETO leukemia. Advances in experimental medicine and biology 962: 151-173 (2017).
  4. Goyama S, *Kitamura T.
    Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. Cancer Science 108(4): 553-562 (2017).